An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease on Hemodialysis (GIFT-R)

Trial Profile

An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease on Hemodialysis (GIFT-R)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms GIFT-R
  • Sponsors AbbVie
  • Most Recent Events

    • 02 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 24 Aug 2016 Planned initiation date changed from 1 Jul 2016 to 1 Sep 2016.
    • 24 Aug 2016 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top